G protein coupled receptors (GPCRs) are the largest family of receptors for hormones and neurotransmitters and therefore the largest group of targets for new therapeutics for a very broad spectrum of diseases including neuropsychiatric, cardiovascular, pulmonary and metabolic disorders, cancer and AIDS. While initially thought to signal exclusively though G proteins and function as two-state switches activated by hormones and neurotransmitters, research over the past 30 years has revealed that most GPCRs have complex and diverse signaling behaviors. A single GPCR can activate more than one G protein subtype as well as G protein independent signaling pathways such as arrestins. Many GPCRs exhibit basal, agonist independent activity. When considering one of the several possible downstream signaling pathways, a drug acting at the orthosteric binding pocket may exhibit one of four efficacy profiles. It may behave as an inverse agonist, suppressing basal activity, a full agonist, maximally activating the pathway, a partial agonist, promoting submaximal activity even at saturating concentrations, or a neutral antagonist, having no effect on basal signaling, but blocking the binding of other orthosteric ligands. The efficacy profile of a given ligand may differ for different signaling pathways such that a drug may behave as an agonist for a specific G protein subtype or arrestin while have no effect or inhibiting other signaling pathways. This pathway selective (or biased) signaling has become an important consideration for drug discovery, since one signaling pathway may produce therapeutic effects while another may lead to adverse effects. During the previous funding period we have applied crystallography and several biophysical methods to characterize the structure and dynamic character of the ?2 adrenergic receptor (?2AR). These studies provide evidence that the ?2AR is highly dynamic and conformationally complex. We hypothesize that this complexity is essential for their functional versatility, and believe that a more detailed understanding of this complex conformational landscape will provide mechanistic insights into targeted activation of a specific pathway with biased ligands. The goal of this proposal will be to understand the structural basis for GPCR signaling through multiple pathways using methods that will provide high-resolution structural constraints and characterize protein dynamics under more physiologic conditions.
The goal of this proposal is to determine the mechanism by which G protein coupled receptors (GPCRs) respond to hormones and neurotransmitters, and modify the function of cells by activating G proteins, kinases and arrestins. This information will facilitate the process of drug discovery for GPCRs, which are the largest family of membrane proteins in the human genome. Drugs acting on GPCRs can have an impact on a broad spectrum of diseases including: cardiovascular disease, pulmonary disease, inflammation, diabetes and obesity, behavioral disorders and Alzheimer?s disease.
Showing the most recent 10 out of 96 publications
